- Demonstrates Further Proof-of-Mechanism of Probody ™ Platform – - Consistent with CX-072 Clinical Observations at 2018 ASCO and ESMO Presentations- - Company to Host Analyst and Investor Event and Webcast Tomorrow, Saturday, November 10 th - SOUTH SAN FRANCISCO, Calif. , Nov.

SOUTH SAN FRANCISCO, Calif. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, will present

ESMO Presentations Support CX-072 Product Profile and Probody™ Proof-of-Concept  Advancement of Clinical Stage Probody Drug Conjugate Programs, CX-2009 and CX-2029  CX-188 IND Filing Marks Fifth Probody Therapeutic to Advance in Clinical Development  Company to Host a Conference Call Today at

PROCLAIM-CX-072 Clinical Translational Data Presented as Poster and Rapid-Fire Oral Presentation Company to Host Analyst and Investor Event and Webcast SOUTH SAN FRANCISCO, Calif. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX) a clinical-stage oncology-focused

SOUTH SAN FRANCISCO, Calif. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, plans to

- Additional Data Supports PD-L1 Targeting Probody CX-072 as Well Tolerated with Antitumor Activity as Monotherapy and in Combination with Ipilimumab - - Company to Host Conference Call and Webcast Today, Monday, October 22 nd at 2:30 p.m. CEST / 8:30 a.m. EDT - SOUTH SAN FRANCISCO, Calif. , Oct.

Update from PROCLAIM-CX-072 trial of a PD-L1 Probody therapeutic as a monotherapy and in combination with ipilimumab SOUTH SAN FRANCISCO, Calif. , Oct. 08, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel

SOUTH SAN FRANCISCO, Calif. , Sept. 25, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, announced

- Presentation of First-in-Human Data Demonstrated Encouraging Safety and Efficacy Profile of CX-072 as Monotherapy and in Combination with ipilimumab (Yervoy®) - - Preliminary Proof-of-Concept for Probody™ Platform and CX-072 - SOUTH SAN FRANCISCO, Calif. , Aug.

SOUTH SAN FRANCISCO, Calif. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, will present